Pivotal ALPHA Phase III trial results will show benefit of danicopan, Alexion’s first-in-
class Factor D inhibitor, in improving clinically significant extravascular haemolysis
while allowing patients with PNH to remain on standard of care treatment
Calquence data will reinforce role as a preferred treatment option for chronic
lymphocytic leukaemia and mantle cell lymphoma
Interim clinical data will show promise of AZD0486, a novel T-cell engager for patients
with relapsed or refractory follicular lymphoma
/Public Release. View in full here.
